RB1 and glioblastoma: While DYRK1A inhibition enhanced the apoptotic efficacy of imatinib by disrupting DREAM complex in quiescent gastrointestinal cancer cells45, in glioblastoma cells, the anti-dormancy efficacy of DYRK1A inhibition is a result of CDK1 activation and is effective only in RB-deficient cells.